(Q35108798)

6 August 2017

0 references

Chemotherapy in gastric cancer: a review and updated meta-analysis (English)

1 reference

6 August 2017

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

24 December 2023

3

Bengt Glimelius

1 reference

6 August 2017

Karl-Gunnar Janunger

1

1 reference

6 August 2017

Larsolof Hafström

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

full work available at URL

6 August 2017

http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1080%2F11024150201680005

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

https://onlinelibrary.wiley.com/doi/full/10.1080/11024150201680005

24 December 2023

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

British Journal of Surgery

24 December 2023

published in

1 reference

The European journal of surgery

6 August 2017

168

11

597–608

2002

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12699095

24 December 2023

volume

168

1 reference

6 August 2017

issue

11

1 reference

6 August 2017

page(s)

597-608

1 reference

Preoperative intraperitoneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications

6 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study

24 December 2023

2

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Paclitaxel and concurrent radiation for gastric cancer

24 December 2023

3

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer

24 December 2023

4

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results

24 December 2023

6

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach.

24 December 2023

7

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation

24 December 2023

8

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).

24 December 2023

9

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles

24 December 2023

10

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma: The Gastrointestinal Tumor study Group

24 December 2023

11

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group

24 December 2023

12

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant treatments following curative resection for gastric cancer. The Italian Gastrointestinal Tumor Study Group

24 December 2023

13

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer

24 December 2023

14

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer.

24 December 2023

15

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

24 December 2023

17

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

24 December 2023

19

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

24 December 2023

20

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin

24 December 2023

21

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk

24 December 2023

22

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Preoperative chemotherapy for unresectable gastric cancer

24 December 2023

23

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer

24 December 2023

24

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

24 December 2023

25

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist

24 December 2023

26

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

[Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese]

24 December 2023

27

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Neoadjuvant chemotherapy for high-grade advanced gastric cancer

24 December 2023

28

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination

24 December 2023

29

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer

24 December 2023

30

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer

24 December 2023

31

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma

24 December 2023

32

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma

24 December 2023

33

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction

24 December 2023

35

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial

24 December 2023

36

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer

24 December 2023

37

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer

24 December 2023

38

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study

24 December 2023

39

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A systematic overview of chemotherapy effects in breast cancer

24 December 2023

40

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

24 December 2023

42

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Long term (five-year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study

24 December 2023

44

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy

24 December 2023

45

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

24 December 2023

46

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant chemotherapy for resectable gastric cancer: a preliminary report

24 December 2023

47

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer

24 December 2023

48

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews

24 December 2023

49

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study

24 December 2023

50

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report

24 December 2023

51

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Use of Triethylenethiophosphoramide as an Adjuvant to the Surgical Treatment of Gastric and Colorectal Carcinoma

24 December 2023

52

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials

24 December 2023

54

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275).

24 December 2023

56

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up

24 December 2023

57

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Chemotherapy of carcinoma of the stomach

24 December 2023

58

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

24 December 2023

59

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection

24 December 2023

60

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement

24 December 2023

62

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma.

24 December 2023

63

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study

24 December 2023

64

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study

24 December 2023

65

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Oncology in the nordic countries--the role of Acta Oncologica?

24 December 2023

66

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

24 December 2023

68

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer.

24 December 2023

69

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients

24 December 2023

70

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up

24 December 2023

72

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.

24 December 2023

73

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials

24 December 2023

74

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A veterans administration surgical oncology group report

24 December 2023

75

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Gastric carcinoma treated by chemotherapy after resection: a controlled study

24 December 2023

76

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A systematic overview of chemotherapy effects in gastric cancer

24 December 2023

79

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial.

24 December 2023

80

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A pilot study of intraperitoneal cisplatin in the management of gastric cancer

24 December 2023

81

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil

24 December 2023

82

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

24 December 2023

84

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Pilot study of combined treatment with continuous infusion of 5-fluorouracil, mitomycin C, and cisplatin (FMP) in patients with inoperable advanced gastric cancer

24 December 2023

85

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

24 December 2023

86

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer

24 December 2023

87

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.

24 December 2023

88

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer

24 December 2023

89

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program

24 December 2023

90

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies

24 December 2023

92

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer

24 December 2023

93

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer

24 December 2023

94

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study

24 December 2023

95

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer

24 December 2023

96

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente).

24 December 2023

98

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Progress in gastric cancer surgery in Japan and its limits of radicality

24 December 2023

99

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial

24 December 2023

100

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan

24 December 2023

101

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan

24 December 2023

102

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer

24 December 2023

103

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

24 December 2023

104

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen

24 December 2023

105

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

24 December 2023

106

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group

24 December 2023

109

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer

24 December 2023

110

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study

24 December 2023

111

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer

24 December 2023

112

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer

24 December 2023

113

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.

24 December 2023

114

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil

24 December 2023

118

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: a prospective randomised trial

24 December 2023

120

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

24 December 2023

121

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence

24 December 2023

122

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

24 December 2023

124

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology

24 December 2023

125

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer

24 December 2023

126

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study

24 December 2023

127

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

24 December 2023

128

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum

24 December 2023

129

1 reference

https://api.crossref.org/works/10.1080/11024150201680005

24 December 2023

Identifiers

1 reference

6 August 2017

1 reference